QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours-PR Newswire APAC

  • STELFONTA (tigilanol tiglate injection) is now approved by the U.S. Food and Drug Administration's Center for Veterinary Medicine for the treatment of non-metastatic mast cell tumours (MCT) in dogs, making it the first pharmaceutical treatment available for all grades of canine non-metastatic MCT[1]
  • FDA approval follows the early 2020 marketing...

Read more: QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours-PR Newswire APAC

More Articles …

  1. Online Education Services (OES) Acquires Majority Stake in Construct-PR Newswire APAC
  2. Sydney puts on a show for Qantas Centenary-PR Newswire APAC
  3. Ralph Lauren Named as Official Outfitter of the Australian Open-PR Newswire APAC
  4. Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases-PR Newswire APAC
  5. PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020-PR Newswire APAC
  6. Guardforce AI Bolsters its Services with Cybersecurity Offering and Robot as a Service Solution-PR Newswire APAC
  7. InfraRisk, Wagepay launch digital wage advance product to disrupt fintech market in Australia-PR Newswire APAC
  8. Arçelik Named Industry Leader in the Dow Jones Sustainability Index Once Again-PR Newswire APAC
  9. Gilead Sciences Announces Recipients of its First Asia HIV Research Scholar Program-PR Newswire APAC
  10. CommsChoice becomes Australia's first vendor of Contact Centre for Microsoft Teams Direct Routing-PR Newswire APAC